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Abstract Vascular endothelial growth factor (VEGF) and
its receptors (VEGFR) are central components in the
development and progression of glioblastoma. To investi-
gate if genetic variation in VEGF and VEGFR2 is associ-
ated with glioblastoma prognosis, we examined blood
samples from 154 glioblastoma cases collected in Sweden
and Denmark between 2000 and 2004. Seventeen tagging
single nucleotide polymorphisms (SNPs) in VEGF and 27
in VEGFR2 were genotyped and analysed, covering 90%
of the genetic variability within the genes. In VEGF, we
found no SNPs associated with survival. In VEGFR2, we
found two SNPs significantly associated to survival,
namely rs2071559 and rs12502008. However, these results
are likely to be false positives due to multiple testing and
could not be confirmed in a separate dataset. Overall, this
study provides little evidence that VEGF and VEGFR2
polymorphisms are important for glioblastoma survival.
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Introduction
Gliomas are the most common type of primary brain
tumour. The most aggressive of these is glioblastoma,
which is associated with very poor prognosis. Apart from
age and performance status, few prognostic factors have
been identified. Potential prognostic markers found in
blood or serum have, however, been proposed, including
polymorphisms in low penetrance genes, such as epidermal
growth factor (EGF) [1–3], and immune function genes, for
instance interleukin 4 (IL4) [4]. Furthermore, hyperme-
thylation of the O6-methylguanine-DNA methyltransferase
(MGMT) gene has been found more frequently in long-
term survival patients with glioblastoma [5].
Vascular endothelial growth factor (VEGF) is a key
factor in both angiogenesis and progression of malignant
brain tumours. It has a pro-angiogenic function and
increases vascular permeability. Overexpression of VEGF
has been found in high grade astrocytoma where its
expression also correlates with poor prognosis [6, 7]. Aside
from the paracrine effect on endothelial cells, it has
recently been shown that VEGF secreted from astrocytoma
cells also has an autocrine effect on cell growth and via-
bility. This is mediated via VEGFR2 (KDR), which is co-
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expressed with VEGF by astrocytoma cells, and involves
co-activation of the c-Raf/MAPK, P13 K/Akt and PLC/
PKC pathways [6]. The effect is diminished by VEGFR2
inhibition. Furthermore, it has been demonstrated that
following radiotherapy there is an inverse correlation
between tumour growth rate and expression of both VEGF
and VEGFR2 by cancer-related stromal cells, in a subcu-
taneous mouse model of human colorectal adenocarci-
noma. This is consistent with the angiogenic regeneration
hypothesis for radiation failure [8]. In the same mouse
model, stroma-secreted VEGF was shown to upregulate the
VEGFR2 pathway in cancer cells through paracrine inter-
actions, which may also help to explain radiation failure.
VEGFR2 inhibition potentiates ionising radiation-induced
tumour cell death [6].
We have performed a comprehensive tagging and
analysis of germline genetic variants in VEGF and VEG-




Tumour and blood samples were collected from 176 glio-
blastoma (ICD-O code 94403) patients diagnosed between
September 2000 and March 2004 in Sweden and Denmark,
as part of the international Interphone study [9, 10]. The
blood samples were mostly collected within 2 months of
diagnosis. A pathology review was performed by two
pathologists (T.B. and H.B.). The patients were all between
20 and 69 years of age, and the male/female ratio was 109/
67. Clinical data regarding (1) date of diagnosis, (2) fol-
low-up date, (3) surgery, (4) radiotherapy and (5) chemo-
therapy was collected (Table 1). Of these, 50 cases were
able to undergo a gross total resection and the remaining
cases underwent a subtotal resection or a biopsy. In all, 40
cases received first line therapy containing temozolomide,
further information on how the therapy was given and if it
was concomitant with radiotherapy was not available.
Other chemotherapy regimes given were CCNU (Lomus-
tine), Vincristine and in a few cases NOC (a combination
of CCNU, Vincristine and Procarbazin). Different doses of
radiotherapy were given, 53 cases received a total dose
between 59 and 60 Gray (Gy), 56 cases 50–58 Gy and the
remaining cases had total doses from 20 to 44 Gy. The
variations of doses were either due to premature termina-
tion due to side-effects or progression, or palliative versus
curative intention up front. Information on one or more of
the treatment parameters was unobtainable in a number of
cases, as follows; all treatment data (6 cases), surgery (9
cases), radiotherapy (1 case) and chemotherapy (23 cases).
The follow-up time for each patient lasted from date of
diagnosis until date of death, alternatively date of last
follow-up in the medical journal. Time to last follow-up
varied between the different centres. Ten cases were
excluded from further analysis due to missing follow-up
data and an additional 12 cases were excluded due to
missing date of diagnosis; thus, 154 cases remained for the
final analyses. A separate dataset was used for confirma-
tion, available from MD Anderson Cancer Center, con-
sisting of 570 glioblastoma cases genotyped with Illumina
Infinium HD Human610-Quad BeadChips, as part of a
recently performed genome-wide association study [11].
SNP selection
The single nucleotide polymorphisms (SNPs) selected for
genotyping were accessed from the public databases: dbSNP
(http://www.ncbi.nih.gov), HapMap (http://www.hapmap.
org/) and SNPper (http://snpper.chip.org/). Twenty-seven
and 17 specific tagging SNPs were selected for genotyping
of VEGFR2 and VEGF, respectively, in order to tag the
linkage disequilibrium (LD) and to gain genotype data both
from within and surrounding the genes. The SNP selection
was performed using the Tagger tool in the Haploview
software (http://www.broad.mit.edu/mpg/haploview), with
a minimum r2 of 0.9. A 5% minor allele frequency was used
in HapMap CEPH (CEU: Utah residents with ancestry from
northern and western Europe), to ensure that an LD block
inferred information from each SNP in the tag-set.
Genotyping
DNA extraction was performed by means of conventional
methods and quantified using PicoGreen (Invitrogen,
Carlsbad, CA, USA). The genotyping was validated on 14
family trios, i.e. 42 individuals, from which genotype data
were available through the HapMap consortium. Concor-
dance analyses based on the HapMap data were performed,
as well as analyses of the parent–offspring compatibility of
the produced genotypes.
As an internal concordance analysis, 90 samples had all
included SNPs genotyped in duplicate. Furthermore, to
monitor the analytical variability, three separate DNA
samples were analysed in quadruplicate on each 364-well
plate used. For each SNP genotyping assay, the success
rate was calculated as the number of genotypes retrieved
divided by the possible number of genotypes.
SNPs genotyping was performed in multiplex format
utilising matrix-assisted laser desorption/ionisation time-
of-flight mass spectrometry (MALDI-TOF-MS). The SNP
assays were designed using the SpectroDESIGNER soft-
ware (Sequenom, USA). PCR amplification took place in a
5-ll mixture containing 10 ng genomic DNA, 100 nM of
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each amplification primer, 500 mM dNTP mix, 1.625 mM
MgCl2, and 5.5 units HotStarTaq DNA Polymerase (Qia-
gen). The mixture was subjected to the following PCR
conditions: a single denaturation cycle at 95C for 15 min,
followed by 45 cycles at 94C for 20 s, 56C for 30 s, 72C
for 60 s and a final extension at 72C for 3 min. The Mass
EXTEND Reagent Kit was used for the allele-specific
extension, in a total of 9 ll with 5 pmol extension primer.
The products were cleaned using SpectroCleaner (Seque-
nom) before being loaded on a 384-element chip nanolinter
pipetting system (Sequenom) and subsequently analysed on
a MassARRAY mass spectrometer (Bruker Daltonik,
Germany). Data analysis was performed using the Spec-
troTyper software (Sequenom), by two persons
independently.
Statistical methods
Cox-regression modelling was used to estimate survival
time as hazard ratios (HR) for carrying different genetic
variants of the VEGF or VEGFR genes, with the major
allele set as the categorical variable. The analyses were
performed using the SPSS software and the HR were
adjusted for country, sex, age, surgery (gross total resection
or not), radio- and chemotherapy. Rs2071559 was available
for confirmation in a data set of 570 glioblastomas col-
lected and analysed at the MD Anderson Cancer Center
[11].
Results
The concordance between the Hap Map data and the data
produced on the Hap Map trios was 100% for all SNPs. No
parent–offspring incompatibility was found. The three
samples that were analysed repeatedly on each analysis
unit consistently showed concordant genotypes for all
assays. The success rate for the different SNP assays were
all in the range of 96.5–98%.
We analysed 27 tagging SNPs in VEGFR2 and 17 tag-
ging SNPs in VEGF for association with glioblastoma
outcome. In VEGF, we found no significant associations.
In VEGFR2, we found one SNP, rs12502008 mapping to
intron 1, where homozygosity for the rare allele was
associated with longer survival (HR = 0.45, 95% CI
0.21–0.95; adjusted for sex, age, country and treatment),
Table 1 Distribution of various characteristics of treatment and survival in 176 glioblastoma from Sweden and Denmark
Sweden (n = 108) Denmark (n = 68) Total (n = 176)
Total Missing Total Missing Total Missing
Survival (months)
Mean 16.1 15.1 15.7
Median 12.4 14.2 12.8
Range 2.1–71.8 1.0–51.9 1.0–71.8
Gross total resection, n (%) 6 (5.6%) 1 (1.5%) 169 (96.0%) 7 (4.0%)
Yes 26 (24.1%) 24 (35.3%) 50 (29.6%)
No 76 (70.4%) 43 (63.2%) 119 (70.4%)
Chemotherapy, n (%) 13 (12.0%) 10 (14.7%) 153 (86.9%) 23 (13.1%)
Yes 69 (63.9%) 14 (20.6%) 83 (54.2%)
Temozolomide 29 (42.0%) 11 (78.6%) 40 (48.2%)
No 26 (24.1%) 44 (64.7%) 70 (45.8%)
Radiotherapy, n (%) 7 (6.5%) 2 (2.9%) 167 (94.9%) 9 (5.1%)
Yes 90 (83.3%) 57 (83.8%) 147 (88.0%)
Total dose 59–60 Gy 13 (14.4%) 40 (70.2%) 53 (36.1%)
Total dose 50–58 Gy 54 (60.0%) 2 (12.3%) 56 (38.1%)
Total dose \50 Gy 16 (17.8%) 7 (12.3%) 23 (15.6%)
Total dose unknown 7 (7.8%) 8 (14.0%) 15 (10.2%)
No 11 (10.2%) 9 (13.2%) 20 (12.0%)
Number of deaths, n (%) 92 (85.2%) 10 (9.3%) 66 (97.1%) 158 (89.8%) 10 (5.7%)
Sex, n (%) 176 (100%)
Male 66 (61.1%) 43 (63.2%) 109 (61.9%)
Female 42 (38.9%) 25 (36.8%) 67 (38.1%)
Age median (years) 56 56 56
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compared to homozygosity for the common allele. We
found no such significant association when we compared
heterozygote genotypes with genotypes homozygote for the
common allele. In another SNP, rs2071559, located in the
promoter region, we saw an association with shorter sur-
vival for heterozygote cases compared to homozygote
cases for the major allele (HR = 1.68, 95% CI 1.06–2.67;
adjusted for sex, age, country and treatment), but here we
did not see any significant difference between the homo-
zygote cases for the minor allele and those homozygous for
the major allele. All results are shown in Table 2.
Rs2071559 was not associated with survival in the MD
Anderson Cancer Center dataset (HR = 1.10, 95% CI
0.97–1.24). Rs12502008 was not available in the MD
Anderson Cancer Center dataset derived from the Illumina
Infinium HD Human610-Quad BeadChips [11].
Discussion
We have performed a comprehensive tagging of the VEGF
and VEGFR2 genes, and an evaluation of their genomic
variation’s prognostic impact in glioblastoma, and this is,
to our knowledge, the first study investigating this corre-
lation. The prognostic impact of VEGF and its receptors
has been studied in several different types of cancers, for
example breast cancer and colorectal cancer [12, 13]. We
did not have tumour tissue available to correlate VEGF/
VEGFR2 genotypes to other known prognostic factors in
glioblastoma [14].
In the VEGF gene, we found no SNPs associated with
survival. In the VEGFR2 gene, we found 2 SNPs, one in
the promoter region (rs2071559) and one in intron 1
(rs12502008), associated with glioblastoma outcome. We
judge our findings as most likely to be false positives. Out
of the total of 44 analysed SNPs, we found 2 with a sig-
nificant association to glioblastoma outcome. This is
equivalent to the number of expected false positives,
considering that the tests were performed at a 95% confi-
dence level. Moreover, none of the SNPs we found to be
significant displayed a clear dose-response (Table 2),
which further supports our assumption. Rs2071559 was
confirmed as a false positive through additional testing in
an external dataset of 570 glioblastomas, available from the
MD Anderson Cancer Center, where it showed no associ-
ation to survival (HR = 1.10, 95% CI 0.97–1.24).
Rs12502008 was not available in the MD Anderson Cancer
Center dataset. In the VEGF family, three receptors have
been identified but earlier studies have shown that activa-
tion of VEGFR2 is sufficient to elicit all proangiogenic,
proliferation and survival effects associated with VEGF.
Although there are three known members of the VEGFR
family, activation of VEGFR2 alone is sufficient to bring
forth all these effects [8]. Furthermore, inhibition of
VEGFR2 has been shown to increase tumour cell death
induced by ionising radiation [6]. Taken together, this
suggests that VEGFR2 plays a crucial role in glioblastoma
development, prognosis, and response to therapy. Genetic
variations in this receptor could therefore be of importance
for the outcome of these tumours. This hypothesis is,
however, not supported by our current study.
Bevacizumab, a monoclonal antibody towards VEGF,
has recently been approved for treatment of recurring
glioblastoma and is currently the standard second line
glioblastoma treatment at many centres. However, none of
the patients in this study received Bevacizumab. Hence, we
could not evaluate the VEGF and VEGFR2 gene variants’
association to response in relation to Bevacizumab treat-
ment. This is nonetheless a highly relevant issue that
potentially could have a large impact on treatment decision
making [15], and should as such be addressed in future
studies including datasets with more homogeneously trea-
ted patients that have received anti-angiogenic therapies. In
conclusion, our study did not provide support for the
hypothesis that polymorphisms in VEGF or VEGFR have
an impact on glioblastoma prognosis.
Table 2 SNPs in the VEGFR2 gene associated with glioblastoma prognosis in cases collected between 2000 and 2004 as part of the Interphone
study
rs number Gene Region Major allele Genotype No. (%) HR (95% CI) P value Median survival time
rs2071559 VEGFR2 Promotor C CC 39 (26.0) 1.0 14.0
CT 72 (48.0) 1.68 (1.06–2.67) 0.028 12.1
TT 39 (26.0) 0.90 (0.52–1.56) 0.702 13.9
rs12502008 VEGFR2 Intron 1 G GG 56 (37.1) 1.0 12.5
GT 77 (51.0) 1.09 (0.74–1.62) 0.659 12.8
TT 18 (11.9) 0.45 (0.21–0.95) 0.036 14.7
All hazard ratios (HR) are adjusted for country, sex, age, surgery, radio- and chemotherapy
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